Ligand Pharmaceuticals (FRA:LGDN) Other Current Receivables: €1.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LGDN Ligand Pharmaceuticals Inc FRA:LGDN
78 GF Score
Price €266.00
GF Value €150.69
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ligand Pharmaceuticals Other Current Receivables?

Ligand Pharmaceuticals FRA:LGDN -1.48% 78 Other Current Receivables is €1.2 Mil as of Mar. 2026. GuruFocus rates FRA:LGDN with a GF Score™ of 78/100 and a GF Value™ of €150.69 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Ligand Pharmaceuticals's Other Current Receivables for the quarter that ended in Mar. 2026 was €1.2 Mil.

Ligand Pharmaceuticals's quarterly Other Current Receivables increased from Sep. 2025 (€0.46 Mil) to Dec. 2025 (€1.24 Mil) but then stayed the same from Dec. 2025 (€1.24 Mil) to Mar. 2026 (€1.22 Mil).

Ligand Pharmaceuticals's annual Other Current Receivables declined from Dec. 2023 (€5.86 Mil) to Dec. 2024 (€3.89 Mil) and declined from Dec. 2024 (€3.89 Mil) to Dec. 2025 (€1.24 Mil).

Ligand Pharmaceuticals Other Current Receivables Related Terms

Ligand Pharmaceuticals Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Ligand Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals Other Current Receivables Chart

Ligand Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.48 4.36 5.86 3.89 1.24

Ligand Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.01 0.72 0.46 1.24 1.22
FRA:LGDN
78GF Score
Ligand Pharmaceuticals Inc FRA:LGDN
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ligand Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €1.2 Mil mean?
Ligand Pharmaceuticals (FRA:LGDN) has a Other Current Receivables of €1.2 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Ligand Pharmaceuticals and its competitors.
Is Ligand Pharmaceuticals' Other Current Receivables too high?
Ligand Pharmaceuticals' current Other Current Receivables is €1.2 Mil. Overall, Ligand Pharmaceuticals has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' Other Current Receivables compare to DFTX and CGON?
Ligand Pharmaceuticals' Other Current Receivables of €1.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current Other Current Receivables is €1.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €150.69, compared to a current price of €266.00 — trading 76.5% above its estimated fair value. The current Other Current Receivables is €1.2 Mil. Ligand Pharmaceuticals' overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Other Current Receivables is €1.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €266.00 is trading 76.5% above its estimated GF Value™ of €150.69. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:LGDN:

  • Other Current Receivables: €1.2 Mil
  • GF Value™: €150.69 vs. price of €266.00 (76.5% above fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ligand Pharmaceuticals Business Description

Other Exchanges LGND:USA
Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
78GF Score

Get the complete analysis for FRA:LGDN

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€266.00
Price
€150.69
GF Value